Ceribell vs Hyperfine
CBLL and HYPR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBLL and HYPR compare
Ceribell is the larger company, worth 14 times as much as Hyperfine ($1.1B against $75.4M).
Hyperfine grew revenue faster over the last twelve months (80.0% versus 31.7% for Ceribell).
Ceribell keeps more of each dollar of sales as profit, with a net margin of −64.7% compared with −156% at Hyperfine.
Hyperfine scores higher on the StockData Score (8 against 6 for Ceribell), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBLL | HYPR |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $75.4M |
| Share price | $27.80 | $0.711 |
| Change, 1 year | 136% | −30.9% |
| Change, 5 years | – | −92.9% |
| Beta (5Y) | 0.84 | 1.05 |
| Employees | 327 | 102 |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 | 4 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.5× | 4.0× (better) |
| P/B | 8.3× | 2.4× (better) |
| FCF yield | −5.1% (better) | −37.0% |
| Fair value | $11.11 | $0.772 |
| Margin of safety | −150% | 7.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 31.7% | 80.0% (better) |
| Revenue growth, 5Y average | – | 115% |
| Profitability | ||
| Gross margin | 88.9% (better) | 52.6% |
| Operating margin | −68.6% (better) | −168% |
| Net margin | −64.7% (better) | −156% |
| FCF margin | −53.7% (better) | −146% |
| Return on equity | −43.9% (better) | −102% |
| Return on invested capital | −331% (better) | −403% |
| Financial health | ||
| Debt / equity | 0.16 (better) | 0.42 |
| Interest coverage | −38.6× | – |
| Current ratio | 9.18 (better) | 5.10 |
| Altman Z-score | 14.89 (better) | −7.43 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 79.5% | 20.6% |
| Held by insiders | 26.7% | 18.1% |
| Insider net buying, 12 months | −$22.4M | −$91.9K (better) |
| Short interest, % of float | 7.0% | 4.5% |
Go deeper
- CBLL stock overview
- CBLL income statement
- CBLL valuation and score
- HYPR stock overview
- HYPR income statement
- HYPR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.